Caris Life Sciences, Inc.
CAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $412 | $306 | $258 | $294 |
| % Growth | 34.7% | 18.4% | -12.1% | – |
| Cost of Goods Sold | $233 | $217 | $178 | $110 |
| Gross Profit | $179 | $89 | $80 | $184 |
| % Margin | 43.4% | 29.2% | 31% | 62.6% |
| R&D Expenses | $114 | $117 | $101 | $0 |
| G&A Expenses | $174 | $152 | $156 | $27 |
| SG&A Expenses | $322 | $291 | $295 | $27 |
| Sales & Mktg Exp. | $148 | $140 | $138 | $0 |
| Other Operating Expenses | $0 | $1 | $0 | $18 |
| Operating Expenses | $436 | $409 | $396 | $45 |
| Operating Income | -$257 | -$320 | -$316 | $139 |
| % Margin | -62.4% | -104.4% | -122.2% | 47.3% |
| Other Income/Exp. Net | -$25 | -$22 | -$5 | -$110 |
| Pre-Tax Income | -$282 | -$341 | -$321 | $30 |
| Tax Expense | $0 | $0 | $0 | $2 |
| Net Income | -$282 | -$341 | -$321 | $28 |
| % Margin | -68.4% | -111.5% | -124.1% | 9.4% |
| EPS | -2.7 | -1.82 | -1.57 | 1.55 |
| % Growth | -48.4% | -15.9% | -201.3% | – |
| EPS Diluted | -2.7 | -1.82 | -1.57 | 1.55 |
| Weighted Avg Shares Out | 255 | 255 | 255 | 18 |
| Weighted Avg Shares Out Dil | 255 | 255 | 255 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $11 | $1 | $0 |
| Interest Expense | $50 | $32 | $27 | $62 |
| Depreciation & Amortization | $49 | $49 | $48 | $111 |
| EBITDA | -$183 | -$261 | -$246 | $254 |
| % Margin | -44.4% | -85.2% | -95.1% | 86.5% |